research report · ABBV

AbbVie Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 3, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 3, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Improving

better on balance: sales, margins, cash or competitive position

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

AbbVie's operating business is getting stronger. Third-quarter 2026 revenue rose 10.3% to $17.4B, because Skyrizi and Rinvoq grew 23–24% and more than offset Humira's 31% decline. Nine-month operating cash flow of $14.9B paid for dividends and buybacks with room left over.

The reported doubling of earnings overstates the gain. The year-earlier quarter carried $2.7B of acquired research charges. Without them, adjusted pre-tax earnings rose about 14% (my calculation).

Two things limit the judgment:

  • Concentration: Skyrizi and Rinvoq were about 49% of quarterly revenue.
  • Debt: borrowing rose $13.4B in nine months to $80.9B, largely to buy a clinical-stage pipeline that management does not expect to add to adjusted earnings until 2032.

what changed this quarter

  • Results: Q3 revenue was $17,404M versus $15,776M a year earlier. Diluted EPS was $2.37 versus $0.10, and adjusted EPS was $3.82 versus $1.86.
  • Guidance: full-year 2026 adjusted EPS guidance rose to $13.95–$13.99 from $13.76–$13.96. It includes a $0.69 drag from research deal charges taken so far this year.
  • Apogee: the acquisition closed September 3 for consideration of $10.6B. It was funded mainly by $10.0B of senior notes issued August 18.
  • Dividend: the quarterly dividend rises 5.2% to $1.82 from the February 2027 payment.
  • Botox pricing: on October 29 a federal court set aside Medicare's selection of Botox for government price-setting. The ruling is subject to appeal.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Skyrizi and Rinvoq carry the company, and their momentum has not slowed
  • The earnings doubling is mostly a comparison effect; the underlying gain is real but smaller
  • Growth is increasingly financed with debt and long-dated obligations
  • Government pricing is the clearest threat outside immunology, and 2027 adds Vraylar

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what ABBV files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on ABBV say?” Add Viridis to Claude, or to ChatGPT.